Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.

Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. · 2022

Read Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. by Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8780712.txt.

Description

Yi and co-authors review combination strategies that pair PD-1 or PD-L1 blockade with other cancer treatments. These antibodies free T cells from an exhausted state. Ten PD-1 and three PD-L1 antibodies have won approval across cancers. Yet most patients do not respond to this therapy alone.

For most, this pathway is not the only brake on anti-tumor immunity. Pairs with chemotherapy, radiation, or targeted drugs have shown stronger results. Other partners include more immune drugs, cell transplants, and metabolic agents. Dual-function antibodies add another route. The review weighs current gains and future directions. The aim is higher response rates for more patients.

Catalog record

CREATORYi M, Zheng X, Niu M, Zhu S, Ge H, Wu K.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE141 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8780712

Browse the full library · About the Tower of Babel